Prostate Ca recurrence, death risk greater for smokers

Article

Men with prostate cancer who smoke have an associated increased risk of all-cause, cardiovascular, and prostate cancer-specific death, say the authors of a study from the Harvard School of Public Health, Boston.

Men with prostate cancer who smoke have an associated increased risk of all-cause, cardiovascular, and prostate cancer-specific death, say the authors of a study from the Harvard School of Public Health, Boston.

Smokers in the study also had an increased likelihood of prostate cancer recurrence, the researchers reported in JAMA (2011; 305:2548-55).

"In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said lead author Stacey Kenfield, ScD. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."

Dr. Kenfield and colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32%) due to prostate cancer, 416 (26%) due to cardiovascular disease, and 878 prostate cancer recurrences.

Men with prostate cancer who were current smokers were found to have a 61% increased risk of dying from prostate cancer and a 61% higher risk of recurrence compared with men who never smoked.

Compared with current smokers, men who had quit smoking for 10 or more years had prostate cancer mortality risks similar to those who had never smoked.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Sad surgeon sitting on floor in corridor | Image Credit: © WavebreakMediaMicro - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Kevin Turner MA DM FRCS(Urol), answers a question during a Zoom video interview
A panel of 3 experts on overactive bladder
Related Content
© 2024 MJH Life Sciences

All rights reserved.